- Conditions
- Neural Tube Defects (NTDs), Facial Cleft Defect, Hereditary Oral Clefts
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- Up to 85 Years
- Enrollment
- 7,451 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2425–2448
of 5,936
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cleft Palate, Tube Disorders Eustachian, Velopharyngeal Incompetence Due to Cleft Palate, Velopharyngeal Insufficiency
- Interventions
- EMST150
- Device
- Lead sponsor
- Noel Jabbour
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Viral Infection
- Interventions
- UV-4B 30 mg oral solution, UV-4B 75 mg oral solution, UV-4B 150 mg oral solution, UV-4B X mg (dose to be determined) oral solution, UV-4B Y mg (dose to be determined) oral solution, Placebo
- Drug
- Lead sponsor
- Emergent BioSolutions
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Madison, Wisconsin
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Interventions
- Rivaroxaban, Warfarin
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Renal Insufficiency
- Interventions
- Epetraborole
- Drug
- Lead sponsor
- AN2 Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
- Conditions
- Multiple Sclerosis
- Interventions
- Bafiertam, Tecfidera
- Drug
- Lead sponsor
- Banner Life Sciences LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Asthma
- Interventions
- BI 1744 CL
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 10
- States / cities
- Lakewood, California • Los Angeles, California • San Diego, California + 6 more
- Conditions
- Periodontal Disease, Periodontitis
- Interventions
- Scaling and root planing
- Procedure
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- Not listed
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Advanced Solid Malignancies, Hematologic Malignancies
- Interventions
- MLN0128, paclitaxel, trastuzumab
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 3
- States / cities
- Fort Myers, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
- Interventions
- telephone-based intervention, nicotine replacement therapy, informational intervention, internet-based intervention, questionnaire administration
- Behavioral · Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Pancreatitis
- Interventions
- aprepitant, Placebo
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Xerostomia
- Interventions
- Crest Whitening Emulsions
- Device
- Lead sponsor
- Tufts University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acne Vulgaris
- Interventions
- YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 14 Years to 45 Years · Female only
- Enrollment
- 534 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2004
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 23 more
- Conditions
- Refractory Bone or Joint Infections
- Interventions
- sodium fusidate
- Drug
- Lead sponsor
- Arrevus Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 19
- States / cities
- Fountain Valley, California • San Dimas, California • Sylmar, California + 16 more
- Conditions
- Type 2 Diabetes
- Interventions
- Placebo for Nasulin, Nasulin
- Other · Drug
- Lead sponsor
- CPEX Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 21
- States / cities
- Chandler, Arizona • Escondido, California • La Jolla, California + 17 more
- Conditions
- Pain, Tooth Extraction
- Interventions
- Rofecoxib and Bupivacaine
- Drug
- Lead sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- NIH
- Eligibility
- Not listed
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Oral Mucosal Disorder
- Interventions
- No SLS toothpaste, Medium SLS toothpaste, High SLS toothpaste, Anti-plaque
- Drug · Device
- Lead sponsor
- Solventum US LLC
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Neoplasm, Oral Mucosa, Transplant-Related Disorder
- Interventions
- Topical Phenylephrine Solution
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Small Cell Lung Cancer
- Interventions
- topotecan/cisplatin, etoposide/cisplatin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 760 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 66
- States / cities
- Hoover, Alabama • Chula Vista, California • Fountain Valley, California + 57 more
- Conditions
- Cancer, Solid Malignant Tumors, SCC - Squamous Cell Carcinoma, HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity
- Interventions
- Intra-op PET/CT Specimen Scanner
- Device
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Atopic Dermatitis, Atopic Dermatitis, Unspecified, Eczema, Eczema, Atopic
- Interventions
- etrasimod, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 44
- States / cities
- Fountain Valley, California • Laguna Hills, California • Los Angeles, California + 17 more
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Clofarabine
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Asthma, Bone Density, Low, Oral Steroid-Dependent Asthma (Disorder)
- Interventions
- CT Scan, DXA Scan, Steroid Intake Questionnaire
- Radiation · Other
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 25 Years to 45 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Binge-Eating Disorder
- Interventions
- Centanafadine, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Encino, California + 21 more